Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel

Trastuzumab deruxtecan (T-DXd)—an antibody–drug conjugate targeting the human epidermal growth factor receptor 2 (HER2)—improved outcomes of patients with HER2-positive and HER2-low metastatic breast cancer. Guidance on monitoring and managing T-DXd–related adverse events (AEs) is an emerging unmet...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Joanne Wing Yan, Lee, Soo Chin, Ho, James Chung-man, Park, Yeon Hee, Chao, Ta-Chung, Kim, Sung-Bae, Lim, Elgene, Lin, Ching-Hung, Loi, Sherene, Low, Su Ying, Teo, Lynette Li San, Yeo, Winnie, Dent, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584766/
https://www.ncbi.nlm.nih.gov/pubmed/37552439
http://dx.doi.org/10.1007/s40264-023-01328-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584766/
https://www.ncbi.nlm.nih.gov/pubmed/37552439
http://dx.doi.org/10.1007/s40264-023-01328-x

Ejemplares similares